BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 2, 2009
View Archived Issues
New venlafaxine prodrugs for depression imparted by Solvay
Read More
CrystaX scientists claim Hsp90 inhibitors and their use in cancer therapy
Read More
Sanofi-aventis presents novel PKB inhibitors for cancer
Read More
Novel PARP inhibitors under development at Abbott for the treatment of cancer
Read More
Indeglitazar, a pan-agonist of PPARs, entering phase II trial for type 2 diabetes mellitus
Read More
Gel and intravaginal ring forms of IQP-0528 are being developed as topical HIV microbicides
Read More
EMEA accepts for review Genmab's Arzerra NDA
Read More
MannKind updates NDA submission status for Afresa
Read More
RegeneRx provides update on phase II RGN-137 trial in venous stasis
Read More
Theravance receives FDA complete response letter for telavancin NDA
Read More
Cephalon intends to make a cash takeover offer to Arana
Read More
DSMB recommends continuation of phase III clinical trial of GTx's toremifene
Read More
MedImmune licenses biologics drug for treating asthma from La Jolla
Read More
Serenity completes phase II clinical trial of CPEX Pharmaceuticals' urology drug
Read More
MabThera approved in the E.U. for patients with chronic lymphocytic leukemia
Read More
AstraZeneca receives FDA complete response letter for Seroquel XR sNDA
Read More
Somaxon receives FDA complete response letter for Silenor
Read More
Phase II study shows potential benefit of erlotinib before cystectomy for bladder cancer
Read More
AZD-0530 inhibits cell growth and migration in human bladder cancer in vitro
Read More
Astellas commences tender offer to acquire outstanding shares of CV Therapeutics
Read More
Nitec completes recruitment in phase III Lodotra trial in rheumatoid arthritis
Read More
FDA approves Symbicort for chronic obstructive pulmonary disease
Read More
The Medicines Company acquires Targanta Therapeutics
Read More
Pharmaxis submits NDA to FDA for Aridol
Read More
Salix receives FDA complete response letter for Metozolv ODT
Read More
Abbott claims new Aurora kinase inhibitors as oncolytic agents
Read More